Biogen, Sage Therapeutics: FDA has no plans to discuss NDA for zuranolone

Sage Therapeutics (SAGE) and Biogen (BIIB) announced that the U.S. FDA notified the companies that the agency does not currently plan to convene an advisory committee meeting to discuss the New Drug Application for zuranolone in the treatment of major depressive disorder and postpartum depression.